URMC Related Haplo-identical Donor BMT

• Status: Completed
• Trial end date: 2021-01-07

Summary

This study will be a single-center treatment protocol, designed to validate the process of related donor haploidentical-SCT at the Wilmot Cancer Institute Blood and Marrow Transplant Unit.

• Phase: Phase 1

Details

• Lead Sponsor: University of Rochester
• Treatments: Busulfan; Cyclophosphamide; Fludarabine; Fludarabine phosphate; Melphalan; Mesna; Thiotepa; Vidarabine